In chronic myelogenous leukaemia (CML), a reciprocal translocation between chromosomes 9 and 22 results in a gene encoding BCR–ABL, a fused deregulated kinase that stimulates cellular ...

As he later recounted, "I had one goal at the time: to find a company that had an inhibitor for bcr-abl and to bring it into the clinic" (Cameron, 2007). Two years later, this chemical ...

Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the ...

Updated Phase 1 data for ELVN-001 expected mid-2025 as positive enrollment momentum continues Expected monotherapy and combination data from the ELVN-002 Phase 1 trials ...

CML diagnoses are confirmed if the Philadelphia chromosome or BCR-ABL gene is detected in bone marrow cells. The course of treatment depends on which phase of the disease a person is in ...